A physiologically based pharmacokinetic model for clobazam and stiripentol in adults and children

Pharmaceutical Research

Volumn 32, Issue 1, 2015, Pages 144-157

  Ogungbenro, Kayode ^a   Aarons, Leon ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

clobazam; dravet syndrome; drug drug interaction; modelling; physiologically based pharmacokinetic model; stiripentol

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CLOBAZAM; N-DESMETHYLCLOBAZAM; STIRIPENTOL;

ADULT; BIOLOGICAL MODEL; BLOOD; CHILD; COMPUTER SIMULATION; DRUG COMBINATION; DRUG INTERACTION; HUMAN; METABOLIC CLEARANCE RATE; METABOLISM; TISSUE DISTRIBUTION;

ADULT; ANTICONVULSANTS; BENZODIAZEPINES; CHILD; COMPUTER SIMULATION; DIOXOLANES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; TISSUE DISTRIBUTION;

EID: 84939884202     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1451-y     Document Type: Article

References (49)

1. Hurst DL. Epidemiology of severe myoclonic epilepsy of infancy. Epilepsia. 1990;31:397-400.
2. Morse RP. Dravet syndrome: inroads into understanding epileptic encephalopathies. J Pediatr. 2011;158:354-9.
3. Chiron C, Dulac O. The pharmacologic treatment of Dravet syndrome. Epilepsia. 2011;52 Suppl 2:72-5.
4. Plosker GL. Stiripentol: in severe myoclonic epilepsy of infancy (dravet syndrome). CNS Drugs. 2012;26:993-1001.
5. Chiron C, Marchand MC, Tran A, Rey E, Athis P, Vincent J, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet. 2000;356:1638-42.
6. Greenblatt DJ, Divoll M, Abernethy DR, Ochs HR, Shader RI. Clinical pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet. 1983;8:233-52.
7. Giraud C, Tran A, Rey E, Vincent J, Treluyer JM, Pons G. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004;32:1279-86.
8. Greenblatt DJ, Divoll M, Puri SK, Ho I, Zinny MA, Shader RI. Clobazam kinetics in the elderly. Br J Clin Pharmacol. 1981;12:631-6.
9. Chiron C. Stiripentol Neurother. 2007;4:123-5.
10. Moreland TA, Astoin J, Lepage F, Tombret F, Levy RH, Baillie TA. The metabolic fate of stiripentol in man. Drug Metab Dispos. 1986;14:654-62.
11. Chhun S, Peigne S, Rey E, Pons G, Jullien V. Population pharmacokinetic study in healthy volunteers treated with 3 single doses of stiripentol (500, 1,000, 2,000 mg). Fundam Clin Pharmacol. 2009;23:24-5.
12. Levy RH, Lin HS, Blehaut HM, Tor JA. Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity. J Clin Pharmacol. 1983;23:523-33.
13. Giraud C, Treluyer JM, Rey E, Chiron C, Vincent J, Pons G, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos. 2006;34:608-11.
14. Tran A, Rey E, Pons G, Rousseau M, d'Athis P, Olive G, et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther. 1997;62:490-504.
15. Levy RH, Loiseau P, Guyot M, Blehaut HM, Tor J, Moreland TA. Stiripentol kinetics in epilepsy: nonlinearity and interactions. Clin Pharmacol Ther. 1984;36:661-9.
16. Valentin J. Basic anatomical and physiological data for use in radiological protection: reference values: ICRP Publication 89. Ann ICRP. 2002;32:1-277.
17. Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr. 1978;93:62-6.
18. DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863-71.
19. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006;45:931-56.
20. Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95:1238-57.
21. Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005;94:1259-76.
22. Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, et al. Population-based mechanistic prediction of oral drug absorption. AAPS J. 2009;11:225-37.
23. Levy RH, Loiseau P, Guyot M, Blehaut HM, Tor J, Moreland TA. Michaelis-Menten kinetics of stiripentol in normal humans. Epilepsia. 1984;25:486-91.
24. Rey E, Jullien V, D'Athis P, Vincent J, Pons G. Is pharmacokinetics of stiripentol linear? Clin Pharmacol Ther. 2005;77:P64-4.
25. Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM User's guides. (1989-2009). Ellicott City: Icon Development Solutions; 2009.
26. Menke G, Pfister P, Sauerwein S, Rietbrock I, Woodcock BG, Rietbrock N. Age-dependence and free fatty acid modulation of binding kinetics at the benzodiazepine binding site of serum albumin in neonates and adults determined using fast reaction methods. Br J Clin Pharmacol. 1987;23:439-45.
27. McNamara PJ, Alcorn J. Protein binding predictions in infants. AAPS PharmSci. 2002;4:E4.
28. Salem F, Johnson TN, Barter ZE, Leeder JS, Rostami-Hodjegan A. Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions. J Clin Pharmacol. 2013;53:857-65.
29. West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science. 1999;284:1677-9.
30. GetData Graph Digitizer, http://getdata-graph-digitizer.com/2013.
31. MATLAB 7.14.0.739. Natick, Massachusetts: The MathWorks Inc. R 2012a.
32. Tedeschi G, Riva R, Baruzzi A. Clobazam plasma-concentrations - pharmacokinetic study in healthy-volunteers and data in epileptic patients. Br J Clin Pharmacol. 1981;11:619-22.
33. Ochs HR, Greenblatt DJ, Luttkenhorst M, Verburg-Ochs B. Single and multiple dose kinetics of clobazam, and clinical effects during multiple dosage. Eur J Clin Pharmacol. 1984;26:499-503.
34. Greenblatt DJ. Electron-capture GLC determination of clobazam and desmethylclobazam in plasma. J Pharm Sci. 1980;69:1351-2.
35. Divoll M, Greenblatt DJ, Ciraulo DA, Puri SK, Ho I, Shader RI. Clobazam kinetics: intrasubject variability and effect of food on adsorption. J Clin Pharmacol. 1982;22:69-73.
36. Bun H, Coassolo P, Gouezo F, Serradimigni A, Cano JP. Time-dependence of clobazam and N-demethylclobazam kinetics in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1986;24:287-93.
37. Greenblatt DJ, Divoll M, Puri SK, Ho I, Zinny MA, Shader RI. Reduced single-dose clearance of clobazam in elderly men predicts increased multiple-dose accumulation. Clin Pharmacokinet. 1983;8:83-94.
38. Pullar T, Edwards D, Haigh JR, Peaker S, Feely MP. The effect of cimetidine on the single dose pharmacokinetics of oral clobazam and N-desmethylclobazam. Br J Clin Pharmacol. 1987;23:317-21.
39. Jawad S, Richens A, Oxley J. Single dose pharmacokinetic study of clobazam in normal volunteers and epileptic patients. Br J Clin Pharmacol. 1984;18:873-7.
40. Vallner JJ, Kotzan JA, Stewart JT, Honigberg IL, Needham TE, Brown WJ. Plasma levels of clobazam after 10-, 20-, and 40-mg tablet doses in healthy subjects. J Clin Pharmacol. 1980;20:444-51.
41. May TW, Boor R, Mayer T, Jurgens U, Rambeck B, Holert N, et al. Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit. 2012;34:390-7.
42. Tran A, Vauzelle-Kervroedan F, Rey E, Pous G, d'Athis P, Chiron C, et al. Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children. Eur J Clin Pharmacol. 1996;50:497-500.
43. Perez J, Chiron C, Musial C, Rey E, Blehaut H, d'Athis P, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia. 1999;40:1618-26.
44. Maharaj AR, Barrett JS, Edginton AN. A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam. AAPS J. 2013;15:455-64.
45. Pullar T, Haigh JR, Peaker S, Feely MP. Pharmacokinetics of N-desmethylclobazam in healthy volunteers and patients with epilepsy. Br J Clin Pharmacol. 1987;24:793-7.
46. Vallner JJ, Needham TE, Jun HW, Brown WJ, Stewart JT, Kotzan JA, et al. Plasma levels of clobazam after three oral dosage forms in health subjects. J Clin Pharmacol. 1978;18:319-24.
47. Rupp W, Badian M, Christ O, Hajdu P, Kulkarni RD, Taeuber K, et al. Pharmacokinetics of single and multiple doses of clobazam in humans. Br J Clin Pharmacol. 1979;7 Suppl 1:51S-7S.
48. L. Inc. Onfi (clobazam) Tablets for oral use: prescribing information 2011.
49. Volz M, Christ O, Kellner HM, Kuch H, Fehlhaber HW, Gantz D, et al. Kinetics and metabolism of clobazam in animals and man. Br J Clin Pharmacol. 1979;7 Suppl 1:41S-50S.